Adjuvant Therapy for Severe Asthma by an Oxyhydrogen Generator With Nebulizer

Not Applicable

• Conditions: Asthma
• Interventions: Device: oxyhydrogen; Device: oxygen

• Registration Number: NCT02883582
• Lead Sponsor: Shanghai Asclepius Meditec Inc.

Brief Summary

The purpose for the trial is intended to evaluate safety and effectiveness of an oxyhydrogen generator with nebulizer in an adjuvant therapy for patients with severe asthma.

Detailed Description

The oxyhydrogen generator with nebulizer in (treatment group) or control group was applied randomly for the patients with severe asthma in this study, then the therapeutic effects from both treatment and control groups were analyzed and evaluated to verify its safety and effectiveness.This study is a multi-center, randomized, double-blind study. Each patient was expected to participate in the trial for 104±3 day.The screening period was 14±1 days, and the subjects would continue to be applied with the previous asthma treatment scheme. The primary objective was to collect the baseline data related to the subjects.The patients would receive 30±1 day of treatment with the product; after that, observation of 60±1 days was required.Total patients number is 150 cases, of which 75 cases are treatment group and the others are control group.All cases respectively are distributed in 5 clinical hospitals.

Study Timeline

• Status Verified: 2016-08
• Study Start: 2016-08
• Study First Submitted: 2016-08-15
• Study First Submitted QC: 2016-08-24
• Last Update Submitted: 2016-08-24
• Study First Posted: 2016-08-30
• Last Update Posted: 2016-08-30
• Primary Completion: 2017-08
• Study Completion: 2017-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

1. Age range: ≥18 years old but ≤65 years old; sex unlimited;

2. The subjects were required to be suffered with asthma for 6 months at least by clinical diagnosis by the respirologist based on the international standards (GINA2012).There was the support of one of the following objective evidences in screening and treatment or five years before the treatment:

   • It was the positive reaction in the methacholine provocative test (for the patients not applied with inhaled corticosteroid (ICS) were required at PC20<8mg/mL and PD20<0.7mg; for the patients applied with ICS were required at PC20<16mg/mL or PD20<1.4mg);

     • The airway reversibility test, with a positive reaction, was defined asΔFEV1.0% at a basis FEV1.0≥200mL at 30 minutes after 400μgsalbutamol aerosol (mist-storing bottle might be used deliberately) was inhaled; ③ The peak expiratory flow (PEF) aberration rate>20% (that is, the difference or average value of maximum and minimum PEFs times 100); it was measured for seven days successively;

       • The reaction record after asthma maintenance treatment for one course of treatment (e.g. four weeks) (defined as ΔFEV1.0 and its absolute value≥200mL);

3. According with severe asthma diagnosis: The drug therapy was required for Level-4 and 5 asthma according to GINA Guide in the past year (The large dose of ICS combined LABA or leukotriene modifier/theophyline), or the systemic corticosteroid treatment lasted at ≥50% of the time to prevent from the "uncontrollable" asthma; or the "uncontrollable" asthma still occurred even if in above treatment. The uncontrollable asthma should meet one of the following requirements at least:

   • Symptom control difference: ACQ>1.5, and ACT<20 (or "Non-good control" in GINA Guide);

     • Frequent severe attack: Receiving systemic corticosteroid treatment for more than twice in the past year (over three days each time); ③ Serious attack: Hospitalizing once in ICU or mechanical ventilation at least in the past year; ④ Airway limitation: After bronchodilator was stopped properly, FEVl.0%<80% (FEV/FVC decreased to be less than lower limit of the normal value). The controlled asthma deteriorated at the decrement of above large dose ICS or systemic corticosteroid (or combined biologic agent);

4. The subjects or their legal agents could understand the trial objectives, demonstrating the compliance to the trail scheme, and signed the Informed Consent Form.

Exclusion Criteria

1. The subjects at a body mass index>38kg/m2, or a weight<40kg;
2. The subjects' smoking amount>10 packages times the year number (e.g. number of cigarettes × the number of years for smoking/20);
3. Based on clinical interview, experience or screening inspection results, the subjects should participate in this trial improperly if the doctor responsible for the trial believed there was risk when they participated in the trial, or the research results were affected;
4. The subjects who had the recreational drug abuse history or other allergic history, but the doctor responsible for the trial believed these subjects limited by the history could participated in the trial;
5. The women subjects who were in the pregnancy or suckling period, or six weeks at least after delivery, or stopped breastfeeding for six weeks. If the women subjects were found to be pregnant in receiving one inspection, then, the inspection data for this item should be rejected in analysis;
6. The subjects ever participated in the study on a new drug or any other drugs, and were within 3 months for the first administration, or every participated in one research involved in invasive operation within 3 months. Any research evaluation should be put off to three months later in the first administration or invasive operation when they participated in the research. It was approved by the steering committee if the subjects participating in other researches were included in trial groups or continued participating in this research;
7. The investigator believed the subjects showed the risk of non-compliance with research procedures;
8. The subjects had the mental disease history resulting in loss of active ability in the recent period;
9. The following disease history or evidences demonstrated within two weeks in baseline assessment that the subjects suffered upper or lower respiratory infections or related symptoms (including common cold) (the assessment should be put off);
10. The subject changed the asthmatic drugs within four weeks before the screening;
11. The subject suffered the asthma attack in the month prior (administered with systemic corticosteroid or temporarily increasing oral corticosteroid at three days of stable base dose at least);
12. Other important diagnoses possibly similar to asthma or complicated asthma, especially respiratory dysfunction, panic attack and evident social psychological problems (if these diagnoses were seen as the patient's main symptoms rather than the symptoms except severe asthma);
13. Other severe primary pulmonary diseases, especially pulmonary embolism, pulmonary hypertension, interstitial pulmonary disease and lung cancer;
14. The subjects with emphysema and bronchiectasis should be excluded only when these diagnoses are considered as their main symptoms rather than other symptoms except severe asthma;
15. The subjects who were diagnosed with other chronic inflammatory diseases (inflammatory bowel disease, rheumatoid arthritis) except asthma.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
oxyhydrogen	oxyhydrogen	conventional treatment (bronchodilator (LABA,LAMA)with or without ICS)+ hydrogen/ oxygen inhaled
oxygen	oxygen	conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ oxygen inhaled

Primary Outcome Measures

Name	Time	Method
differentials from Mini Asthma Quality of life questionnaire (Mini AQLQ)	at 3 months	Mini Asthma Quality of life questionnaire (Mini AQLQ) was used for evaluation on asthma treatment after the subjects were treated, to determine the product effectiveness.

Secondary Outcome Measures

Name	Time	Method
differentials from Special allergens	at 3 months	egg white, milk, fish, wheat, peanut, soybean (fx5); house dust, household dust mites, dust mites, cockroaches (hx2); Penicillium notatum/branch neurospora/Aspergillus fumigatus/Candida yeast/Alternaria neurospora/creep cinerea (mx2); inhaled allergen screening (Phadiatop); total IgE1.
differentials from pulmonary function	at 3 months	Inspection items for patient pulmonary function include: FEV1.0, FEV1.0%, FVC, MMEF, MEF25, MEF50, MEF75, DLCO / VA, PEF †, FeNO, RV, TLC, RV / TLC, and FRC.
differentials from Baseline in Serum interleukin-8( IL - 8)	at 3 months
differentials from Baseline in Serum tumor necrosis factor-a(TNF-a)	at 3 months
differentials from number of asthma acute attacks	at 3 months	The number of asthma acute attacks refers to the total number of the patient's asthma acute attacks in the observation period after the completion of hydrogen treatment.
differentials from Baseline in Serum interleukin-4( IL - 4)	at 3 months
differentials from Baseline in Serum interleukin-5( IL - 5)	at 3 months
differentials from asthma control test (ACT)	at 3 months	The asthma control test (ACT) is used for evaluation of the asthma state after treatment, to determine effectiveness of the product.
differentials from number of uses of first-aid drugs	at 3 months	Number of uses of first aid drugs (short-term beta receptor stimulant) refers to the total number of administering salbutamol for relieving symptoms in the efficacy observation period after each subject completed hydrogen treatment.
differentials from blood routine examination	at 3 months
differentials from routine urine test	at 3 months
differentials from 12-lead ECG test	at 3 months
differentials from Baseline in Serum interleukin-6(IL-6)	at 3 months
differentials from Baseline in Serum interleukin-13( IL - 13)	at 3 months
differentials from Baseline in Serum interleukin-17( IL - 17)	at 3 months
differentials from asthma control questionnaire	at 3 months	the asthma control questionnaire (ACQ) was used for the evaluation on the subjects' asthma state after treatment, to determine effectiveness of the product.
differentials from serum C reactive protein (CRP)	at 3 months
differentials from liver function examination	at 3 months
differentials from renal function examination	at 3 months
differentials from electrolyte test	at 3 months
differentials from urine pregnancy test for fertile women	at 3 months
differentials from Peak Expiratory Flow (PEF) daily aberration rate	at 3 months	Peak Expiratory Flow (PEF) refers to the instant flow rate in the fastest expiratory flow in the forced vital capacity measurement process, mainly reflecting the strength of respiratory flow and airway obstruction.
differentials from airway resistance measurement	at 3 months	The patient airway resistance was measured was measured, including: Rat5Hz, Rat20Hz, Xat5Hz, MeanR5\~R20 and AX.
differentials from induced sputum test	at 3 months	proportions of eosinophils, macrophages, lymphocytes, and neutrophils;

Trial Locations

Locations (1)

the First Affiliated Hospital of Guangzhou Medical University; 🇨🇳 Guangzhou, Guangdong, China